Stock Updates

How has Alexion Pharmaceuticals, Inc.:(NASDAQ:ALXN) performed recently?

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) is a large market cap stock with a market cap of 26476.06. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 163.84, a forward P/E of 17.85 and EPS of 0.72. At a stock price of 117.64 (-0.80%) it has a dividend yield of *TBA.

EPS growth for the last five years have been 5.10%, more recently this last year it has grown by -79.50%. The next year growth is going to be about 30.32% and more long-term 20.34% after five years. EPS growth quarter over quarter is -10.10%. Sales growth for the past five years have been 36.90% and sales growth quarter over quarter is 16.80%.

For performance, Alexion Pharmaceuticals, Inc. the past week has seen a gain of 5.14%. For the last month performance for Alexion Pharmaceuticals, Inc. is -23.56%. While the last quarter is -20.53% and half year, -36.30%. Finally for the year, performance is -36.83%.

The 52-week high for Alexion Pharmaceuticals, Inc., is at -43.68%, and for the 52-week low it comes to a value of 6.40%. The 20-day simple moving average is -14.94% and -23.87% for the 200-day simple moving average.

Volatility for the week is at 3.00%, and for the month it is 3.04%. Alexion Pharmaceuticals, Inc., has a target price of 185.83.

In terms of debt, long term debt/equity is 0.4, and for total debt/equity Alexion Pharmaceuticals, Inc. has 0.4. The gross margin is 91.80%, while operating margin is 22.10%, the profit margin is 5.40%. The current ratio is 3.5 and the quick ratio is 3.

Insider ownership is at 0.60%, with instituitional ownership at 98.70%. Alexion Pharmaceuticals, Inc. has a payout ratio of 0.00%. With the total shares outstanding coming to 225.06. The shares float is 223.19, with the float short at 2.13%, with short ratio coming to 2.6.

In terms of returns, the return on assets see Alexion Pharmaceuticals, Inc., get 1.10%, with its returns on investment at 1.60%. Return on equity is 1.80%. So will the investors see the target price of 185.83, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Tony Dabbs

Leave a Comment